LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today reported financial results for the first quarter ended March 31, 2015 and provided an operational update.
“We remain encouraged by the progress of our ganetespib clinical program including enrollment in our pivotal, Phase 3 GALAXY-2 trial in non-small cell lung adenocarcinoma, and the broad investigator-led trial effort, which includes large, ongoing randomized trials in acute myeloid leukemia and ovarian and breast cancers,” said Chen Schor, President and Chief Executive Officer of Synta.
Help employers find you! Check out all the jobs and post your resume.
“We remain encouraged by the progress of our ganetespib clinical program including enrollment in our pivotal, Phase 3 GALAXY-2 trial in non-small cell lung adenocarcinoma, and the broad investigator-led trial effort, which includes large, ongoing randomized trials in acute myeloid leukemia and ovarian and breast cancers,” said Chen Schor, President and Chief Executive Officer of Synta.
Help employers find you! Check out all the jobs and post your resume.
